Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 5/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23324181 | 0.85 | HSD17B10 (0.35) | DPP8DPP7GAAHSD17B10MAPT | |
| SCHEMBL20060297 | 0.81 | NR1D1 (0.37) | EGLN1EPHX2 | |
| SCHEMBL25906961 | 0.79 | GAA (0.37) | GAAHSD17B10MAPTHTR1A | |
| SCHEMBL25953691 | 0.78 | MEN1 (0.39) | GAAHSD17B10MAPT | |
| SCHEMBL23324612 | 0.75 | MEN1 (0.37) | GAAHSD17B10MAPT | |
| SCHEMBL25594290 | 0.74 | CYP1A2 (0.41) | MAPTEPHX2 | |
| SCHEMBL23338576 | 0.74 | MEN1 (0.36) | DPP8DPP7GAAHSD17B10MAPT | |
| SCHEMBL25958806 | 0.74 | DPP8 (0.35) | DPP8DPP7GAAHSD17B10EPHX2 | |
| SCHEMBL23342596 | 0.73 | MAPT (0.39) | GAAHSD17B10MAPT | |
| SCHEMBL25909060 | 0.73 | CNR1 (0.31) | GAAHTR1ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | DPP8 2342/4885DPP7 2572/4885GAA 2164/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | DPP8 2342/4885DPP7 2572/4885GAA 2164/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | DPP8 2342/4885DPP7 2572/4885GAA 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.